RVMD Earnings Revolution Medicines, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–20 of 20
| Q1 2026 | 2026-03-31 | -2.29 | 2026-05-06 | 10-Q |
| FY 2025 | 2025-12-31 | -5.95 | 2026-02-25 | 10-K |
| Q3 2025 | 2025-09-30 | -4.06 | 2025-11-05 | 10-Q |
| Q2 2025 | 2025-06-30 | -2.45 | 2025-08-06 | 10-Q |
| Q1 2026 | 2025-03-31 | -1.13 | 2026-05-06 | 10-Q |
| FY 2025 | 2024-12-31 | -3.58 | 2026-02-25 | 10-K |
| Q3 2025 | 2024-09-30 | -2.45 | 2025-11-05 | 10-Q |
| Q2 2025 | 2024-06-30 | -1.51 | 2025-08-06 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.70 | 2025-05-07 | 10-Q |
| FY 2025 | 2023-12-31 | -3.86 | 2026-02-25 | 10-K |
| Q3 2024 | 2023-09-30 | -2.65 | 2024-11-06 | 10-Q |
| Q2 2024 | 2023-06-30 | -1.65 | 2024-08-07 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.72 | 2024-05-08 | 10-Q |
| FY 2024 | 2022-12-31 | -3.08 | 2025-02-26 | 10-K |
| Q3 2023 | 2022-09-30 | -2.47 | 2023-11-06 | 10-Q |
| Q1 2023 | 2022-06-30 | -1.60 | 2023-08-08 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.78 | 2023-05-08 | 10-Q |
| FY 2023 | 2021-12-31 | -2.57 | 2024-02-26 | 10-K |
| Q3 2022 | 2021-09-30 | -1.85 | 2022-11-07 | 10-Q |
| Q2 2022 | 2021-06-30 | -1.13 | 2022-08-09 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.